Compare Celsius Holdings, Inc. (CELH) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs TransMedics Group Inc — how do they compare? Celsius Holdings, Inc. trades at $27.63 (market cap $6.99B), while TransMedics Group Inc trades at $87.67 (market cap $3.02B). The key difference: Celsius Holdings, Inc. is far larger — about 2.3× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| CELH | TMDX | |
|---|---|---|
Market Cap | $6.99B | $3.02B |
Sector | Consumer Staples | Technology |
52-Week High | $64.86 | $150.42 |
52-Week Low | $23.77 | $61.99 |
Enterprise Value | $8.79B | $3.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CELH trades at $27.48, up 0.99% on the day, but remains under bearish technical pressure with key resistance at $29. The company reported Q2 2026 earnings that missed expectations, with revenue growth slowing to 11% year-over-year as core brand sales weakened, though Alani Nu and Rockstar acquisitions provided some offset. Net cash flow was negative $350.20 million in 2025 due to significant investing activities.
Outlook is mixed; strong analyst buy consensus (95.65%) and a $44.08 price target suggest long-term confidence in growth via PepsiCo partnership, but near-term risks include execution challenges, margin pressure, and ongoing investigations into management disclosures. The stock's high P/E of 122.13 reflects growth expectations that must materialize to justify valuation.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
